Soley Therapeutics Appoints Berthil Clasen, PhD, MBA, as Chief Business Officer

Former Eli Lilly business development executive joins to lead partnerships and corporate strategy as Soley Therapeutics advances its lead oncology programs toward the clinic SOUTH SAN FRANCISCO, Calif., June 7, 2026 — Soley Therapeutics (“Soley”), a science-first, tech-enabled drug discovery and development company using cellular sensing to discover first-in-class medicines, today announced the appointment of […]

Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026

Data highlight biomarker-linked activity and in vivo efficacy of STX-6398, supporting small-molecule CKAP2 modulation as a novel therapeutic approach in cancer SOUTH SAN FRANCISCO, Calif., April 17, 2026  — Soley Therapeutics, a biotechnology company advancing novel therapeutics informed by integrated cell stress biology, today announced the presentation of new preclinical data at the American Association […]

Soley Therapeutics to Unveil a First-in-Class Small Molecule CKAP2 Modulator with Selective Anti-Tumor Activity at AACR 2026

Preclinical data demonstrate how Soley’s proprietary drug discovery platform translates cell stress biology into first-in-class drug candidates SOUTH SAN FRANCISCO, Calif., March 17, 2026 — Soley Therapeutics, a biotechnology company advancing novel therapeutics informed by integrated cell stress biology, today introduced STX-6398, a first-in-class drug candidate with selective anti-tumor activity through modulation of cytoskeleton-associated protein 2 […]